IQVIA Holdings Inc. $IQV Shares Sold by Marks Group Wealth Management Inc

Posted by George Bondi on Jun 9th, 2026

Marks Group Wealth Management Inc reduced its holdings in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 15.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 40,995 shares of the medical research company’s stock after selling 7,368 shares during the quarter. IQVIA accounts for 0.9% of Marks Group Wealth Management Inc’s portfolio, making the stock its 22nd largest position. Marks Group Wealth Management Inc’s holdings in IQVIA were worth $9,241,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Ameliora Wealth Management Ltd. acquired a new stake in IQVIA in the 4th quarter valued at approximately $25,000. International Assets Investment Management LLC acquired a new stake in IQVIA in the 4th quarter valued at approximately $27,000. Measured Wealth Private Client Group LLC acquired a new stake in IQVIA in the 3rd quarter valued at approximately $30,000. Activest Wealth Management increased its position in IQVIA by 590.0% in the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 118 shares during the period. Finally, Hilton Head Capital Partners LLC acquired a new stake in IQVIA in the 4th quarter valued at approximately $35,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Price Performance

Shares of NYSE:IQV opened at $183.64 on Tuesday. The company’s fifty day moving average is $172.42 and its two-hundred day moving average is $194.55. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a 12-month low of $151.58 and a 12-month high of $247.04. The company has a market cap of $30.65 billion, a P/E ratio of 22.76, a price-to-earnings-growth ratio of 1.57 and a beta of 1.21.

IQVIA (NYSE:IQV – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same period in the previous year, the company posted $2.70 EPS. IQVIA’s revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities analysts expect that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA declared that its board has approved a stock repurchase plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s leadership believes its stock is undervalued.

Wall Street Analysts Forecast Growth

IQV has been the topic of several analyst reports. Royal Bank Of Canada initiated coverage on IQVIA in a research report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 target price on the stock. HSBC set a $210.00 price target on IQVIA in a research note on Wednesday, June 3rd. Morgan Stanley set a $225.00 price target on IQVIA in a research note on Thursday, May 7th. Weiss Ratings lowered IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Finally, TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and increased their price target for the company from $174.00 to $213.00 in a research note on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, IQVIA presently has a consensus rating of “Buy” and an average price target of $224.13.

Read Our Latest Analysis on IQVIA

IQVIA Profile

(Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

IQVIA Holdings Inc. $IQV Shares Sold by Marks Group Wealth Management Inc

IQVIA Price Performance

Wall Street Analysts Forecast Growth

IQVIA Profile

See Also

You might be interested in: